27 July 2017 – final results
The group has announced its final results for the year to 30 April revealing a loss before tax of £7.4m (2016: loss of £5.4m) although given the stage of the group’s development this is not surprising. Of more importance is the fact that the group continues to make progress with its Parsortix liquid biopsy system. At the end of the year the company had cash balances of £5.5m following a fund-raising during the year and we are optimistic that eventually the system will prove to be successful and investors will be rewarded accordingly. LONG TERM BUY.